Preclinical studies of potential amyloid binding PET/SPECT ligands in Alzheimer's disease

被引:27
|
作者
Svedberg, Marie M. [1 ,2 ]
Rahman, Obaidur [3 ]
Hall, Hakan [1 ,2 ]
机构
[1] Uppsala Univ, Dept Med Chem, Preclin PET Platform, SE-75183 Uppsala, Sweden
[2] Uppsala Univ, Dept Publ Hlth & Caring Sci, SE-75183 Uppsala, Sweden
[3] Oslo Univ Hosp, Norwegian Med Cyclotron Ctr, Oslo, Norway
关键词
Alzheimer's disease; Amyloid plaques; Molecular imaging; Positron emission tomography; Preclinical evaluation; POSITRON-EMISSION-TOMOGRAPHY; MILD COGNITIVE IMPAIRMENT; PITTSBURGH COMPOUND-B; PET IMAGING AGENTS; TRANSGENIC ANIMAL-MODELS; THIOFLAVIN-T-BINDING; IN-VIVO DETECTION; MOUSE MODEL; MONOCLONAL-ANTIBODY; STILBENE DERIVATIVES;
D O I
10.1016/j.nucmedbio.2011.10.007
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Visualizing the neuropathological hallmarks amyloid plaques and neurofibrillary tangles of Alzheimer's disease in vivo using positron emission tomography (PET) or single photon emission computed tomography will be of great value in diagnosing the individual patient and will also help in our understanding of the disease. The successful introduction of [C-11]PIB as a PET tracer for the amyloid plaques less than 10 years ago started an intensive research, and numerous new compounds for use in molecular imaging of the amyloid plaques have been developed. The candidates are based on dyes like thioflavin T, Congo red and chrysamine G, but also on other types such as benzoxazoles, curcumin and stilbenes. In the present review, we present methods of the radiochemistry and preclinical evaluation as well as the main properties of some of these compounds. (C) 2012 Elsevier Inc. All rights reserved.
引用
收藏
页码:484 / 501
页数:18
相关论文
共 50 条
  • [1] Amyloid binding ligands as Alzheimer's disease therapies
    Lee, VMY
    [J]. NEUROBIOLOGY OF AGING, 2002, 23 (06) : 1039 - 1042
  • [2] Development of a PET/SPECT agent for amyloid imaging in Alzheimer's disease
    Wang, YM
    Klunk, WE
    Debnath, ML
    Huang, GF
    Holt, DP
    Shao, L
    Mathis, CA
    [J]. JOURNAL OF MOLECULAR NEUROSCIENCE, 2004, 24 (01) : 55 - 62
  • [3] Development of a PET/SPECT agent for amyloid imaging in Alzheimer’s disease
    Yanming Wang
    William E. Klunk
    Manik L. Debnath
    Guo-Feng Huang
    Daniel P. Holt
    Li Shao
    Chester A. Mathis
    [J]. Journal of Molecular Neuroscience, 2004, 24 : 55 - 62
  • [4] PET amyloid-beta imaging in preclinical Alzheimer's disease
    Vlassenko, Andrei G.
    Benzinger, Tammie L. S.
    Morris, John C.
    [J]. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE, 2012, 1822 (03): : 370 - 379
  • [5] Asymmetric amyloid deposition in preclinical Alzheimer's disease: A PET study
    Kjeldsen, Pernille L.
    Parbo, Peter
    Hansen, Kim, V
    Aanerud, Joel F. A.
    Ismail, Rola
    Nissen, Peter H.
    Dalby, Rikke B.
    Damholdt, Malene F.
    Borghammer, Per
    Brooks, David J.
    [J]. AGING BRAIN, 2022, 2
  • [6] Alzheimer's Disease: SPECT and PET Tracers for Beta-Amyloid Imaging
    Valotassiou, V.
    Archimandritis, S.
    Sifakis, N.
    Papatriantafyllou, J.
    Georgoulias, P.
    [J]. CURRENT ALZHEIMER RESEARCH, 2010, 7 (06) : 477 - 486
  • [7] Preclinical diagnosis of Alzheimer's disease with SPECT
    Johnson, KA
    Jones, KJ
    Becker, JA
    Holman, BL
    Satlin, A
    Albert, MS
    [J]. NEUROLOGY, 1997, 48 (03) : 24006 - 24006
  • [8] Spatial extent as a sensitive amyloid-PET metric in preclinical Alzheimer's disease
    Farrell, Michelle E.
    Thibault, Emma G.
    Becker, J. Alex
    Price, Julie C.
    Healy, Brian C.
    Hanseeuw, Bernard J.
    Buckley, Rachel F.
    Jacobs, Heidi I. L.
    Schultz, Aaron P.
    Chen, Charles D.
    Sperling, Reisa A.
    Johnson, Keith A.
    [J]. ALZHEIMERS & DEMENTIA, 2024, 20 (08) : 5434 - 5449
  • [9] Reactions to learning a "not elevated" amyloid PET result in a preclinical Alzheimer's disease trial
    Grill, Joshua D.
    Cox, Chelsea G.
    Harkins, Kristin
    Karlawish, Jason
    [J]. ALZHEIMERS RESEARCH & THERAPY, 2018, 10
  • [10] Reactions to learning a “not elevated” amyloid PET result in a preclinical Alzheimer’s disease trial
    Joshua D. Grill
    Chelsea G. Cox
    Kristin Harkins
    Jason Karlawish
    [J]. Alzheimer's Research & Therapy, 10